



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 29 Aug 2022 (#34)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-OD-22-195](#) New NIH "FORMS-H" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2023. This notice informs the applicant and recipient communities of changes to grant application forms and application guide instructions for due dates on or after January 25, 2023.

The following application forms include substantive form changes (i.e., new/deleted/modified fields). All other forms include only an OMB expiration date change.

- PHS 398 Research Plan Form
- PHS 398 Career Development Award Supplemental Form
- PHS 398 Research Training Program Plan
- PHS Fellowship Supplemental Form

For NIH, as part of the implementation of the 2023 NIH Data Management and Sharing Policy, a new "Other Plan(s)" attachment field has been added to the PHS 398 Research Plan Form and the PHS 398 Career Development Award Supplemental Form. Applicants must attach the required Data Management and Sharing Plan in this new field in FORMS-H applications. See [NOT-OD-21-013](#) and [NOT-OD-22-189](#) for more information. Note: Although the 2023 NIH

Data Management and Sharing Policy is not applicable to fellowship and institutional training grant applications, the new attachment field was added for potential future use with other plans.

[NOT-OD-22-189](#) Implementation Details for the NIH Data Management and Sharing Policy. The purpose of this notice is to inform the extramural research community of implementation details for the [NIH Policy for Data Management and Sharing \(DMS Policy\)](#) affecting grant and cooperative agreement applications submitted for receipt dates on or after January 25, 2023. The specific changes to competing grant and cooperative agreement application instructions clarified below will be implemented with application form packages identified with a Competition ID of “FORMS-H” and incorporated into the forthcoming FORMS-H application guides. Although the DMS Policy will apply also to Research and Development (R&D) contracts, NIH intramural research projects, and other funding agreements (e.g., Other Transactions), the forms changes and other implementation details provided in this Notice apply only to NIH extramural grant and cooperative agreement activities. Details applicable to R&D contracts will be incorporated into the appropriate Requests for Proposals, and details applicable to Other Transactions will be incorporated into the appropriate Research Opportunity Announcement.

[NOT-OD-22-190](#) Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022. This notice informs the community of NIH and AHRQ application due date adjustments to accommodate scheduled federal system downtime. Grants.gov has a planned production system outage from Friday, September 23, 2022 at 12:01 AM ET to Thursday, September 29, 2022 at 11:59 PM ET (see [Grants.gov calendar](#)). Grants.gov will use this time to migrate their services to the Cloud. In response, NIH and AHRQ due dates that fall on or between September 22 and September 30, 2022 will move to October 3, 2022.

3rd cohort of the African Postdoctoral Training Initiative (APTI) fellowships. APTI Training early career scientists to respond to Africa's challenges in global health. Nairobi, Kenya | Tuesday 16 August 2022. The African Academy of Sciences ([AAS](#)), in partnership with the U.S. National Institutes of Health ([NIH](#)) and the Bill & Melinda Gates Foundation ([BMGF](#)), announces a call for applications for the 3rd cohort of the African Postdoctoral Training Initiative ([APTI](#)) fellowships. APTI Fellows are trained and supported to become scientific leaders who can advocate for increased research and innovation projects in Africa. This is done through 4-year postdoctoral fellowships where APTI Fellows are placed in various laboratories of the NIH Institutes or Centers (i.e., Intramural Research Program) for 2 years before returning to their home institutions in Africa for another 2 years of research. Ultimately, APTI fellows are expected to be a part of an African regional and global web of collaborations connecting to their home institutions.

APTI fellowships are open to applications from fields of health research, with a focus on innovation aimed at the discovery and translation of transformative solutions to global health problems that are priorities for their home institutions and countries. Additionally, proposals should align with the focus areas of [BMGF](#), the [NIH](#), and the [AAS](#).

To be eligible, applicants must:

- Be citizens of an African country, currently employed in an academic, research, or government position in an African country
- Have a relevant doctoral degree (e.g., PhD, MD, MBBS) awarded no more than 7 years before the application submission deadline. Applicants whose doctoral degrees were awarded earlier may be considered on a case-by-case basis subject to justification (e.g., where one took a career break for family-related reasons or to seek asylum due to political instability). Such applicants should submit a request (with justification) for consideration
- Have less than 5 years of relevant research experience after the award of their doctoral degree, by their start date at the NIH. Brief periods of clinical work and/or teaching, that does not include research, may be allowable, but cannot exceed 2-3 years total.
- Be fluent in English – reading, writing, speaking, and listening.

Additional information:

- All applications and their supporting documents must be submitted in English. Supporting documents issued in a language other than English should be accompanied by their English translation.
- Applications must be submitted via the [AAS Grants Management system](#) (Ishango).

Submission of applications opens on **16 August 2022** and closes on **30 September 2022**, at 17:00 East African Time (GMT +3).

[NOT-HL-22-045](#) Notice of Intent to Publish a Funding Opportunity Announcement for Pediatric Heart Network Clinical Research Centers (UM1). The National Heart, Lung, and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications from qualified institutions

willing to participate with NHLBI in the [Pediatric Heart Network \(PHN\)](#) as Clinical Research Centers (CRCs). These Clinical Research Centers will be expected to support and conduct research to improve the health and quality of life for children and adults with congenital heart disease through multi-center collaborative clinical research. Expected Number of Awards =9. Estimated Award = Up to \$450,000 per award in FY2024. First Estimated Application Due Date: 23 February 2023.

[NOT-AI-22-073](#) Pre-Solicitation Notice: Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA), RFP: 75N93022R00015. The primary purpose of the Mycobacterium tuberculosis Quality Assessment (TBQA) contract is to support and promote access to quality-assured MTB laboratory diagnosis and testing across laboratories participating in DAIDS-supported clinical trials. MTB laboratories play a critical role in generating data that determine primary and secondary endpoints for TB clinical trials. The harmonization of methodologies among the various testing laboratories (Labs) ensures comparability of test results across multiple trial-supporting labs and comparability of data between trials. The use of appropriate methodologies and reliable test results ensures the safety of study participants and supports product advancement and approval by U.S. and non-U.S. regulatory entities. The TBQA will continue to serve current and future NIAID-sponsored clinical trial networks, cohorts, and collaborating study groups (User Groups), as well as individual grantees conducting clinical research. The current contract is held by MRIGlobal, Kansas City, MO, under contract number HHSN272201700001C. The period of performance of the current contract is January 1, 2017 through December 31, 2023.

The purpose of the proposed contract will be to provide a Mycobacterium tuberculosis (MTB) Quality Assessment Program (TBQA), a resource to: (1) support the ability of laboratories (Labs) to reliably perform study-specified MTB tests; (2) evaluate MTB technologies and specimen processes for use in clinical investigations; and (3) disseminate technical and scientific data. This contract also includes Options to increase level of effort in support of: (1) unanticipated increases in demand related to support of additional Labs; (2) performance of late-stage assay validation and/or MTB assay testing of clinical samples in a CLIA-certified laboratory; and (3) public health emergency needs. The TBQA will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the U.S. Examples of NIAID-sponsored Networks include the Adult AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT) and the HIV Vaccine Trials Network (HVTN). Examples of NIAID-sponsored TB cohorts include the India and Brazil Regional Prospective Observational Research for Tuberculosis (RePORT). Any responsible offeror may submit a proposal, which will be considered by the Agency. This RFP will be available electronically, on/about August 31, 2022.

[NOT-DA-23-005](#) Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy. This NOSI invites applications for administrative supplements to existing awards to add and/or expand biospecimen collection during and immediately after pregnancy to build prospective pathophysiological models of maternal, neonatal, and infant risk and disease related to prenatal opioid use or exposure during pregnancy. Prenatal opioid use during pregnancy can significantly increase the risk for neonatal opioid withdrawal syndrome (NOWS) in newborns, and contribute to a host of maternal health and behavioral outcomes, including altered maternal caregiving behaviors and chronic stress. This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through October 8, 2023.

Funding Opportunity Announcements (FOA)

1. The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-234](#)

Type: U01

Application Due Date: 9 November 2022 through to 20 June 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Cancer Institute's (NCI) Metastasis Research Network (MetNet) is a collection of U54 Research Centers that support using systems-level approaches to understand pressing questions in metastasis. The overall goal of the MetNet is to advance our understanding of metastasis as a whole body, systems-level problem to develop a comprehensive and cohesive picture of the processes involved. Through this Funding Opportunity Announcement (FOA), the NCI invites applications for MetNet Research Projects. These Research Projects should be defined as discrete entities that use systems-level approaches to address gaps and opportunities in metastasis research to integrate into the MetNet and complement ongoing research across the Network.

Budget: Application budgets are limited to a maximum of \$500,000 in direct costs per year and need to reflect the actual needs of the proposed project. Project periods of up to 5 years may be proposed.

2. Maintaining Immunity after Immunization (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-22-055](#)

Type: U01

Application Due Date: 13 January 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this Funding Opportunity Announcement (FOA) is to promote research to improve our understanding of how vaccines against infectious agents lead to durable protective immunity. This initiative will support studies that define components and mechanisms of the immune system that determine such durability. Applications must propose the use of human cells/tissues to decipher the human response elicited through vaccination. Animal studies also may be included to elucidate mechanistic pathways not easily accomplished with human samples.

Budget: NIAID intends to commit \$4.8 M in FY 2024 to fund 5-8 awards. Application budgets are not expected to exceed \$450,000 in direct costs per year, and should reflect the actual needs of the project. The scope of the proposed project should determine the project period. The maximum project period is five years.

3. HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-EB-22-002](#)

Type: R18

Application Due Date: 14 November 2022 through to 17 June 2025. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to develop clinical-grade prototype devices intended for use as safe, effective, and non-addictive diagnostics and treatments for pain or opioid use disorder (OUD). The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain or OUD, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain or OUD. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use.

Budget: NIH intends to commit an estimate of \$6,000,000 to fund approximately 8-12 awards in fiscal year 2023. Application budgets are not limited, but need to reflect the actual needs of the proposed project. Budgets should rarely exceed \$750,000 direct cost per year. Applications may request up to three years of support. However, the scope of the proposed project should determine the project period.

4. Physiomimetics and Organoids for Reproductive Health (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-HD-23-024](#)

Type: R01

Application Due Date: 29 March 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications to develop physiomimetic platforms and organoid culture systems for studies of the female reproductive tract and gametogenesis (both male and female) that can be used to uncover factors responsible for gynecological conditions and infertility. This FOA is intended to provide support for the further development of projects where preliminary data supports the feasibility of the line of investigation. Applicants without preliminary data may wish to apply to the companion R21 FOA ([RFA-HD-23-025](#)).

Budget: NICHD intends to commit \$1.6 million in FY 2023 to fund 4-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period and may be up to 5 years.

5. Optimization of Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (U01 - Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-NS-23-017](#)

Type: U01

Application Due Date: 30 November 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This FOA is not specific for any one or group within the AD/ADRD spectrum of disorders. Disorders, and includes genome editing therapies for: Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), Alzheimer's Disease (AD) and Multiples Etiology Dementias (MED).

Budget: NINDS intends to commit a total budget of up to \$ 3,000,000 per year to fund up to 3 awards. Application budgets are limited to no more than \$650,000 in direct costs per year and need to reflect the actual needs of the proposed project. The project period may not exceed 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105